Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 13,784 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: Heart Failure
Interventions: IASD System II implant, intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE); Device · Other
Lead sponsor: Corvia Medical; Industry
Eligibility: 40 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 36 more

Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Interventions: DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Coronado, California • Montclair, California • Panorama City, California + 12 more

Conditions: Memory Impairment
Interventions: Vilazodone, Placebo, Hydrocortisone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Graft-Versus-Host Disease
Interventions: MEDI-507, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Timeline: 1999 – 2000
U.S. locations: 3
States / cities: St Louis, Missouri • Omaha, Nebraska • Dallas, Texas

Conditions: Type 2 Diabetes
Interventions: placebo, exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 40
States / cities: Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more

Conditions: Chronic Liver Disease, Cirrhosis
Interventions: Observational; Other
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 10
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 6 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Conditions: Wounds and Injuries
Interventions: V.A.C.Ulta with Prontosan instillation, V.A.C.Ulta without instillation; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Miami, Florida • Chicago, Illinois + 4 more

Conditions: AMD
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Beverly Hills, California • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, Tozorakimab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 57
States / cities: Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, insulin detemir, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 60
States / cities: Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more

Conditions: Partial Lipodystrophy
Interventions: metreleptin, Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 12 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more

Conditions: Healthy Participants
Interventions: Trastuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Anaheim, California • Daytona Beach, Florida • Springfield, Missouri + 1 more

Conditions: Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions: Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 174
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more

Conditions: Asthma, Wheezing
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Months to 60 Months
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 5 more

Conditions: Substance Dependence
Interventions: GSK598809, Nicotine Replacement Transdermal Patch, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 10
States / cities: DeLand, Florida • Pembroke Pines, Florida • Stockbridge, Georgia + 7 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Dexamethasone, Lenalidomide, Bortezomib, Pomalidomide, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 14
States / cities: Tucson, Arizona • Bakersfield, California • Fountain Valley, California + 11 more

Conditions: Delayed Graft Function
Interventions: QPI-1002, Placebo; Drug · Other
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Cardiovascular Disease
Interventions: Vascular surgery with best medical treatment, Coronary artery bypass grafting (CABG), Percutaneous transluminal coronary angioplasty (PTCA); Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 18
States / cities: Tucson, Arizona • No. Little Rock, Arkansas • San Francisco, California + 15 more

Conditions: Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
Interventions: Total Laparoscopic Hysterectomy; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 71
States / cities: Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more

Conditions: Advanced Liver Cancers
Interventions: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Duarte, California • Orange, California + 11 more

Conditions: Postoperative Sedation, Intubation, Respiration, Artificial
Interventions: AQUAVAN (fospropofol disodium; GPI 15715 ); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Rogers, Arizona • Miami, Florida • Park Ridge, Illinois + 13 more

Search by objective public record fields.

REDUCE LAP-HF TRIAL II

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Vilazodone for Corticosteroid-Induced Memory Impairment

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

An Observational Study of Patients With Chronic Liver Disease

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

A Pilot RCT of Veraflo With Prontosan vs VAC in Wounds Requiring Operative Debridement

Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department

Relapse Prevention Study in Newly Abstinent Smokers

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality

Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting